ArticleFrontiers in endocrinology2026
Association of a novel index, the total cholesterol-high-density lipoprotein-glucose index, with diabetes mellitus in Chinese adults: a retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Research on the relationship between Total Cholesterol, High-Density Lipoprotein, and Glucose (CHG) index and diabetes mellitus (DM) risk remains limited. This study aims to investigate the association between CHG and DM incidence. Methods: This retrospective cohort study included 8,844 participants who underwent comprehensive health examinations at Shenzhen Kuichong People's Hospital between 2018 and 2023. The maximum individual follow-up duration reached 5 years, with a median (interquartile range) follow-up period of 2.72 (2.58-4.78) years. Cox proportional hazards regression models were used to evaluate the association between CHG and DM risk. ROC analysis was conducted to evaluate the predictive capability of CHG for DM. Finally, subgroup analyses and sensitivity analyses were performed to further verify the stability of these findings. Results: After multivariate adjustment, the CHG index was independently associated with increased DM risk, with an HR of 1.150 (95% CI: 1.098-1.204) per 0.1 unit increase in CHG. Furthermore, ROC curve analysis demonstrated that CHG had the highest AUC (0.7377) for predicting DM risk, compared to TC (0.5375), HDL-c (0.6105), and FPG (0.6761). The stability of these results was further validated through sensitivity and subgroup analyses. Conclusion: This study found an independent positive relationship between CHG and DM risk. Additionally, CHG demonstrates a certain predictive value for DM risk. This helps clinicians identify high-risk individuals for DM early and provides a new perspective for optimizing clinical prevention and management of DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.